Published in Nature on February 28, 1970
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol (2006) 1.44
A kinetic evaluation of monoamine oxidase activity in rat liver mitochondrial outer membranes. Biochem J (1974) 1.35
Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol (2001) 1.27
Interactions of monoamine oxidase inhibition and sympathomimetic amines on the human iris. Br J Pharmacol (1971) 0.97
Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease. Neurotherapeutics (2009) 0.86
Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline. Exp Neurobiol (2013) 0.85
Brain amine concentrations after monoamine oxidase inhibitor administration. Br Med J (1972) 0.84
Rasagiline in treatment of Parkinson's disease. Neuropsychiatr Dis Treat (2008) 0.82
Inhibition of monoamine oxidase by (E)-styrylisatin analogues. Bioorg Med Chem Lett (2009) 0.81
Proceedings: Histochemical demonstration of an additional form of rat brain MAO. Br J Pharmacol (1975) 0.80
Monoamine oxidase and aldehyde dehydrogenase activity in the striatum of rats after 6-hydroxydopamine lesion of the nigrostriatal pathway. Br J Pharmacol (1973) 0.79
Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease. Expert Opin Drug Discov (2014) 0.78
Monoamine oxidase: multiple forms and selective inhibitors. Biochem J (1971) 0.78
The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging (2010) 0.77
Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression. J Neural Transm (Vienna) (2015) 0.77
Monoamine Oxidase Inhibitory Activity of Novel Pyrazoline Analogues: Curcumin Based Design and Synthesis. ACS Med Chem Lett (2015) 0.75
New look at monoamine oxidase inhibitors. The new biochemical background. Proc R Soc Med (1973) 0.75
Activation studies of the multiple forms of prochymosin (prorennin). Biochem J (1977) 0.75
Quantum-chemical approach to determining the high potency of clorgyline as an irreversible acetylenic monoamine oxidase inhibitor. J Neural Transm (Vienna) (2013) 0.75
New horizons in psychopharmacology. Proc R Soc Med (1972) 0.75
Atomic structure of graphene on SiO2. Nano Lett (2007) 4.59
Prostaglandin secretion by medullary carcinoma of the thyroid. A possible cause of the associated idarrhoea. Lancet (1968) 3.78
Pathological and clinical findings in a series of 67 cases of medullary carcinoma of the thyroid. J Clin Pathol (1966) 2.99
Prostaglandins in amine-peptide-secreting tumours. Lancet (1968) 2.75
A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer (1979) 2.67
Distribution of prostaglandins in human tissues. Br J Pharmacol Chemother (1967) 2.58
The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer (1989) 2.52
DNA replication licensing and human cell proliferation. J Cell Sci (2001) 2.30
A phenylethylamine oxidising defect in migraine. Nature (1974) 2.28
Demonstration of somatic mutation and colonic crypt clonality by X-linked enzyme histochemistry. Nature (1988) 2.28
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm (1988) 2.10
The release of endogenous amino acids from the rat visual cortex. J Physiol (1976) 2.08
The metabolic fate of DL(7-3H)isoprenaline in man and dog. Biochem J (1969) 2.06
High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene (1989) 1.98
A simple post-embedding system for the rapid demonstration of tissue antigens under the electron microscope. Histochem J (1983) 1.95
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem (1989) 1.94
Age related reactivation of an X-linked gene. Nature (1987) 1.92
Conjugation defect in tyramine-sensitive migraine. Nature (1971) 1.91
Isatin: identity with the purified endogenous monoamine oxidase inhibitor tribulin. J Neurochem (1988) 1.90
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm (1985) 1.89
Pathology of 'nonendocrine' tumors associated with Cushing's syndrome. Cancer (1968) 1.85
Multiple forms of rat brain monoamine oxidase. Nature (1969) 1.77
Properties of purified, soluble monoamine oxidase. Can J Biochem (1966) 1.76
Tumurs, hormones, and cellular differentiation. Lancet (1969) 1.75
Multiple mucosal neuromata with endocrine tumours: a syndrome allied to von Recklinghausen's disease. J Pathol Bacteriol (1966) 1.74
A comparison of two methods for measuring the signal to noise ratio on MR images. Phys Med Biol (1999) 1.71
Links between early post-partum mood and post-natal depression. Br J Psychiatry (1992) 1.71
Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem (1991) 1.70
Use of yttrium 90 in persistent synovitis of the knee. I. Retention in the knee and spread in the body after injection. Ann Rheum Dis (1973) 1.66
Deprenyl in Parkinson's disease. Lancet (1977) 1.66
Racial variation in the O-acetylation phenotype of human colonic mucosa. J Pathol (1994) 1.62
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm (1975) 1.62
Chloroquine-resistant falciparum malaria among British service personnel in West Malaysia and Singapore. Trans R Soc Trop Med Hyg (1971) 1.60
Histogenesis of medullary carcinoma of the thyroid. J Clin Pathol (1966) 1.57
Multiple forms of monoamine oxidase: functional significance. Pharmacol Rev (1972) 1.56
Brain iron pathways and their relevance to Parkinson's disease. J Neurochem (2001) 1.55
Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm. Histopathology (1994) 1.53
Cyclical variations in endometrial monoamine oxidase: correlation of histochemical and quantitative biochemical assays. Biochem Pharmacol (1968) 1.51
Dopamine is a monoamine oxidase B substrate in man. Nature (1977) 1.48
Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem (1994) 1.46
Activated ras oncogenes in human thyroid cancers. Cancer Res (1988) 1.45
Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage (2002) 1.44
Catecholamine metabolism and monoamine oxidase activity in adrenalectomized rats. Biochem Pharmacol (1970) 1.42
Tyramine conjugation test for prediction of treatment response in depressed patients. Lancet (1989) 1.41
Anticholinergic antiparkinsonian drugs in psychiatry. Br J Hosp Med (1991) 1.39
Pressure exerted by head bandages used in otological surgery. J Laryngol Otol (1993) 1.39
Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet (1977) 1.38
Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol (1975) 1.38
The estimation of monoamine oxidase using 14C-labelled substrates. Biochem Pharmacol (1969) 1.38
Exchange of nuclear medicine image files. Nucl Med Commun (1990) 1.38
Metabolism of isoprenaline in dog and man. Br J Pharmacol (1972) 1.38
High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab (1999) 1.37
Defect scattering in graphene. Phys Rev Lett (2009) 1.37
Isatin: a link between natriuretic peptides and monoamines? Biochem Pharmacol (1996) 1.36
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. Neuropharmacology (1976) 1.35
Evaluation of bicuculline as a GABA antagonist. Nature (1971) 1.35
Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol (1978) 1.35
Concurrent estimation of total body and exchangeable body sodium in hypertension. Clin Sci Mol Med (1978) 1.34
Migraine: a pulmonary disease? Lancet (1972) 1.34
The demonstration of tissue clonality by X-linked enzyme histochemistry. J Pathol (1988) 1.33
Oxidative stress: free radical production in neural degeneration. Pharmacol Ther (1994) 1.33
Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology (2001) 1.32
Stress causes an increase in endogenous monoamine oxidase inhibitor (tribulin) in rat brain. Neurosci Lett (1988) 1.31
Thymic and parathyroid origin of calcitonin in man. Lancet (1968) 1.31
Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem (2001) 1.30
Calcitonin receptor antibodies in the identification of osteoclasts. Bone (1999) 1.29
Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'. Psychopharmacology (Berl) (1978) 1.29
Thyroid cancer in an iodide rich area: a histopathological study. Cancer (1977) 1.28
Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect (1990) 1.27
Isoenzymes of human and rat liver monoamine oxidase. FEBS Lett (1968) 1.26
Indirect effects of amino-acids on sympathetic ganglion cells mediated through the release of gamma-aminobutyric acid from glial cells. Br J Pharmacol (1976) 1.25
Crypt restricted heterogeneity of goblet cell mucus glycoprotein in histologically normal human colonic mucosa: a potential marker of somatic mutation. Br J Cancer (1990) 1.25
Value of external quality assessment of the technical aspects of histopathology. J Clin Pathol (1982) 1.24
Effect of iron chelators on dopamine D2 receptors. J Neurochem (1985) 1.22
Tuning the effective fine structure constant in graphene: opposing effects of dielectric screening on short- and long-range potential scattering. Phys Rev Lett (2008) 1.22
Cross-section study of pulmonary function in patients with insulin-dependent diabetes mellitus. Am Rev Respir Dis (1987) 1.21
Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours. Oncogene (1991) 1.20
Calibration and evaluation of a system of total body in vivo activation analysis using 14 MeV neutrons. Phys Med Biol (1978) 1.20
High-fidelity conformation of graphene to SiO2 topographic features. Phys Rev Lett (2010) 1.19
L-Dopa and Parkinsonism. Nature (1970) 1.19
The influence of methimazole on thyroglobulin-induced autoimmune thyroiditis in the rat. Endocrinology (1983) 1.19
Promotion of 4-hydroxy-3-methoxyphenylglycol formation in man by reserpine. Nature (1968) 1.19
Automated histoquantitation studies of bone. Proc R Soc Med (1972) 1.19
Whole body elemental composition during drug treatment of rheumatoid arthritis: a preliminary study. Ann Rheum Dis (1979) 1.18
Use of bromodeoxyuridine for cell kinetic studies in intact animals. Cell Tissue Kinet (1986) 1.17
The Chernobyl thyroid cancer experience: pathology. Clin Oncol (R Coll Radiol) (2011) 1.17
Physical randomization of tissue architecture: an alternative to systemic sampling. J Microsc (1982) 1.17
Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl (1997) 1.16